NeoPharm Signs R&D Agreement With NINDS
Posted on: Thursday, 16 October 2008, 12:00 CDT
NeoPharm, a biopharmaceutical company, has signed a cooperative R&D agreement with the National Institute of Neurological Diseases and Stroke, a part of the National Institutes of Health for research on a therapeutic agent for untreatable brain diseases in humans.
Under the terms of the cooperative R&D agreement, National Institute of Neurological Diseases and Stroke (NINDS) will deliver NeoPharm's proprietary drug, Cintredekin Besudotox (IL13-PE38QQR) (IL-13), in conjunction with a surrogate marker via NINDS's patented methodology of convection enhanced delivery, which was previously licensed to NeoPharm.
The company will provide both the drug and technical resources to study its effects in various brain cancers in humans.
Laurence Birch, president and CEO of NeoPharm, said: "This cooperative R&D agreement serves as another step in pursuing the validation of IL-13's impact on possibly increasing and enhancing the life span of patients diagnosed with terminal brain cancers."
Source: Datamonitor
Related Articles
- American Heart Association Statement Gives Guidance on Minimally Invasive Procedures to Treat Diseased Brain Vessels
- Onward Healthcare Signs National Healthcare Staffing Agreement With VHA Inc.
- Liberty Signs Multi-Year National Strategic Partnership Agreement With the American Diabetes Association
- National Disease Research Interchange Appoints Broxmeyer Board Chairman
- National Disease Research Interchange Receives Funding Commitment for Rare Disease Initiative
- TeliaSonera: Xfera Renews Its National 2G-Roaming Agreement With Vodafone
- B.C. First Nations Sign Education Agreement to Boost Pride and the Grad Rate
- Study: Rich Nations Aiding 'Brain Drain'
- National Telecom Company Agreement to Receive Loan
- Re-Engineering the Diseased Brain
 |
 |
User Comments (0)
RSS Feeds